Innovations in HPAPI Containment & Facility Design for Successful Manufacturing

Sponsored by: Catalent Pharma Solutions and FPS Food and Pharma Systems

Chaired by: Justin Mason-Home, Director, HPAPI Project Services Limited

SMi is delighted to announce its 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference on 10th and 11th May 2021.

Highly Potent Active Pharmaceutical Ingredients (HPAPIs) play an increasing central role in the fight against many diseases. There is an increasing need to protect workers who handle HPAPIs along the life cycle of the drug product manufacturing, from synthesis of the pharmaceutical active ingredient to distribution of the finished medicinal product. This year’s event will focus on 4 key themes: best practices for toxicological assessment, innovations in containment and facility design, advances in the use of robotics and automation in manufacturing processes, and environmental considerations. Key case studies will be highlighted throughout these themes, revealing the key challenges for current HPAPI manufacture, and insights into the latest technological and regulatory advances in this increasingly potent environment.

Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPi industry.

Key Speakers for HPAPi include:

• Ester Lovsin-Barle, Head of Product Stewardship and Health, Takeda
• Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
• Raphael Nudelman, Director of Chemical & Computational Toxicology, Teva Pharmaceutical
• Olindo Lazzaro, Director Global EHS, AbbVie
• Fred Ohsiek, Senior Specialist, Cleaning Validation, Novo Nordisk
• Florian Grundmann, MSAT Team Lead, Cleaning Validation, Roche
• Ildiko Ziegler, QA Manager, Vanessa Research
• Jack Brown, Senior Research Fellow, formerly Boehringer Ingelheim
• Reinhold Maeck, Head of Corp EHS Regulatory Intelligence, Boehringer Ingelheim

Doreen Parrish, Head of Corporate Audit, Global EHS, Takeda

Key Reasons to Attend HPAPi:

• Explore best practices in hazard assessment and occupational toxicology
• understand strategic considerations for planning pilot plants and scaling up manufacturing capabilities for high potency compounds
• discover potential for automation and robotics in pharmaceutical manufacturing and technologies for protecting operators from hazardous substances
• discuss the opportunities for effective CDMO relationships and explore methods for strengthening those partnerships
• Delve into the expanding ADC market within and beyond oncology
• Virtual conference benefits include virtual exhibition booths packed with information, networking features to chat and share contact details with attendees

View the full agenda: www.highlypotentapi.com/PJwl